Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
Status:
Recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the efficacy, safety, pharmacokinetics (PK), and
pharmacodynamics of ALXN1840 versus standard of care in pediatric participants with Wilson
disease (WD).